Thursday, December 5

Tag: Glenmark and BeiGene

Glenmark and BeiGene Enter into an Agreement for Marketing and Distribution of Tislelizumab and Zanubrutinib in India
Business News, Feature, National News

Glenmark and BeiGene Enter into an Agreement for Marketing and Distribution of Tislelizumab and Zanubrutinib in India

New Delhi, Ma y 21, 2024. Glenmark Specialty S.A. (Glenmark), a subsidiary of Glenmark Pharmaceuticals Ltd., a research-led, global pharmaceutical company, today announced an exclusive marketing and distribution agreement with BeiGene, a global oncology company. Under this agreement, Glenmark will register and commercialize BeiGene's oncology medicines, Tislelizumab and Zanubrutinib in India. Speaking on this partnership, Alok Malik, President and Business Head - India Formulations, Glenmark Pharmaceuticals Ltd. said, "We are excited about our partnership with BeiGene, signifying our commitment to advancing healthcare in India. The addition of Tislelizumab and Zanubrutinib to our oncology portfolio underscores our dedication to the cancer patients' community and our commitment to pro...
Verified by MonsterInsights